| Date | Quarter | Session | EPS (est → actual) | Revenue (est → actual) |
|---|---|---|---|---|
| Oct 19, 2026Next | Q3 2026 | Before market open | 1.93 | 6.63 B |
Aug 31, 2026
Danaher has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.
Aug 28, 2026
Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund delivered a 4.32% total return in Q2 2026, underperforming the 13.87% gain for the Russell 1000 Value Index and the 15.20% return for the S&P 500, while […]
Aug 25, 2026
DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.
Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, today announced FDA 510(k) clearance for the Masimo Root® with LiDCO® hemodynamic monitoring solution, including the Masimo LiDCO sensor. This comprehensive solution provides the unique ability to continuously monitor and trend oxygen delivery (DO₂) that reflects changes in both cardiac output and arterial oxygen content.
Making a noteworthy insider sell on August 24, Rainer Blair, President & CEO at Danaher (NYSE:DHR), is reported in the latest SEC filing. What Happened: Blair's decision to sell 58,255 shares of Danaher was
Aug 23, 2026
Healthcare investors often face a difficult decision when choosing between companies with very different paths to growth. Some businesses are emerging from temporary industry slowdowns, while others continue compounding through durable competitive advantages. Danaher Corporation (NYSE:DHR) and Intuitive Surgical (NASDAQ:ISRG) illustrate that contrast perfectly. Danaher (NYSE:DHR) is beginning to benefit from improving life sciences spending […]
Healthcare investors are beginning to see signs of recovery across several parts of the industry, but not every recovery looks the same. Danaher (NYSE:DHR) is benefiting from improving demand in life sciences after a prolonged post-pandemic slowdown, while Medtronic (NYSE:MDT) is finally beginning to show the results of years of investment in new products and […]
Aug 20, 2026
Danaher (DHR) is back in focus after its latest trading session, with the stock closing at $211.50. Investors are weighing this move against the company’s recent total return profile and current fundamentals. See our latest analysis for Danaher. The recent 1 day share price return of 5.97% at US$211.50 comes after a mixed stretch, with a 90 day share price return of 22.02% but a year to date share price return that is down 8.20%. The 1 year total shareholder return of 0.79% signals only...
Danaher stock is coming off a mixed five year stretch, with the share price down 23.5%, and the latest checks suggest the shares are not an obvious bargain even though the Discounted Cash Flow (DCF) estimate points to a level close to the current market price. At the same time, traditional market multiples lean on the expensive side, which leaves investors weighing a fairly valued intrinsic estimate against a richer read on earnings based pricing. Over the past five years, Danaher has...
Aug 16, 2026
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Danaher (NYSE:DHR) and the rest of the research tools & consumables stocks fared in Q2.
Aug 14, 2026
Although Danaher has underperformed relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.
When biopharmaceutical suppliers report earnings, ripples move fast across the sector. On July 21, Danaher Corporation (NYSE:DHR) reported its Q2 2026 results. While the life sciences giant continues to lead in financial scale, its bioprocessing unit missed expectations, signaling continued softness in broader biopharma demand. The news hit European supplier Sartorius AG, which traded lower […]
